Pharmaceutical
intermediates are organic compounds that are primarily used in the
manufacturing and formulation of active pharmaceutical ingredients (APIs) used
in drug development. They aid in synthesizing APIs in a cost-effective manner
by acting as a connecting link in multi-stage chemical reactions. Some common
types of pharmaceutical intermediates include aromatic chemicals, amino acids,
pesticides, polymers, and dyes & pigments. There has been a rise in their
demand over the years owing to the increasing generics drug production
worldwide. The growing geriatric population suffering from chronic diseases is
also fueling the need for affordable treatment options.
The
Global Pharmaceutical Intermediates Market is estimated to be valued at US$ 43.67 Bn in 2024 and is expected to
exhibit a CAGR of 8.1% over the
forecast period 2024 to 2031.
Key Takeaways
Key players operating in the Global Pharmaceutical Intermediates are Evonik,
Borregaard AS, Sudarshan Pharma, A.R. Life Science, Actylis, Saurav Chemicals
Ltd., Lianhetech, Midas Pharma GmbH, Sanofi , BASF SE, Chiracon GmbH, Lonza, Chemcon
Speciality Chemicals Limited., Modepro India Pvt. Ltd., Lifechem Pharma, Sarex,
LANXESS.
Key opportunities in the market include expanding contract manufacturing
capabilities to meet rising API demand from generic drugmakers. Generics
account for over 80% of all prescriptions filled in the US. There is an
increased focus on developing cost-effective treatments.
Globally, the
Global
Pharmaceutical Intermediates Market Size is witnessing high growth in
emerging regions owing to increasing investments by leading market players.
Countries like India and China offer a skilled workforce and favorable business
climate attracting foreign investments. This is expected to drive the global
expansion of pharmaceutical intermediates industry over the forecast period.
Market Drivers: One of the key drivers of the global pharmaceutical
intermediates market is the patent expiration of blockbuster drugs. As patents
of popular drugs expire, generic versions become commercially viable,
increasing generic drug production. This in turn boosts demand for
pharmaceutical intermediates.
Market Restrain: Major restrain hampering the growth of global pharmaceutical
intermediates market includes stringent regulations associated with approval
processes and production of pharmaceutical intermediates. Regulatory
authorities like US FDA imposes strict guidelines to ensure safety, efficacy
and quality which increases costs and compliance requirements. This acts as a
deterrent, particularly for small manufacturers.
Segment Analysis
The global pharmaceutical intermediates market can be segmented by synthesis
type, application and drug. Based on synthesis type, the semi-synthetic
intermediates segment dominated the market in 2024 as various pharmaceutical
bulk drugs and formulations are derived from semi-synthetic routes. By
application, analgesics/pain management dominated as these are widely used for
various conditions including arthritis and injuries. Among drugs, ARV/AAA
(antiretroviral/anti-infective agents) intermediates held majority share due to
large global prevalence of HIV infections.
Global Analysis
Regionally, Asia Pacific was the fastest growing market for pharmaceutical
intermediates during the forecast period. This can be attributed to presence of
large pharmaceutical manufacturing capacities in big countries like India,
China, Japan and South Korea. The bulk drugs and formulations manufacturing
units in these countries require huge and continuous supply of intermediates.
North America was the second largest regional market, dominated by the US which
is one of the largest pharmaceutical markets globally. Strong R&D funding
for new drug development drives demand for various intermediates from the
region. Europe held significant share of the global market, with major
countries being Germany, UK, France, Italy and Spain.
Get more insights on This Topic- Global
Pharmaceutical Intermediates Market
Comments
Post a Comment